Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PENEDERM NDAs FOR RETINOIC ACID GEL AND CREAM FOR ACNE

This article was originally published in The Tan Sheet

Executive Summary

PENEDERM NDAs FOR RETINOIC ACID GEL AND CREAM FOR ACNE have been filed with FDA, the company stated in a May 2 "red herring" prospectus for the offering of 1.7 mil. shares of common stock by Penederm shareholders. Foster City, Calif.-based Penederm said that Phase III trials that enrolled about 400 subjects were completed in the summer of 1993, and both NDAs for the prescription products were originally submitted in September.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel